| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penile Induration | 99 | 2023 | 126 | 30.030 |
Why?
|
| Penis | 58 | 2023 | 81 | 12.920 |
Why?
|
| Erectile Dysfunction | 42 | 2023 | 53 | 11.160 |
Why?
|
| Penile Prosthesis | 29 | 2023 | 35 | 8.500 |
Why?
|
| Penile Implantation | 19 | 2023 | 26 | 7.080 |
Why?
|
| Male | 186 | 2023 | 12453 | 5.130 |
Why?
|
| Patient Satisfaction | 32 | 2023 | 295 | 4.470 |
Why?
|
| Urologic Surgical Procedures, Male | 16 | 2020 | 23 | 4.220 |
Why?
|
| Penile Erection | 24 | 2023 | 25 | 3.970 |
Why?
|
| Spermatic Cord | 12 | 2021 | 16 | 3.930 |
Why?
|
| Humans | 191 | 2023 | 22848 | 3.710 |
Why?
|
| Traction | 15 | 2021 | 31 | 3.700 |
Why?
|
| Verapamil | 16 | 2022 | 20 | 3.530 |
Why?
|
| Penile Diseases | 7 | 2023 | 9 | 3.340 |
Why?
|
| Testicular Diseases | 9 | 2021 | 15 | 3.070 |
Why?
|
| Microbial Collagenase | 9 | 2020 | 13 | 3.070 |
Why?
|
| Denervation | 10 | 2021 | 19 | 2.940 |
Why?
|
| Middle Aged | 83 | 2023 | 7555 | 2.710 |
Why?
|
| Chronic Pain | 6 | 2021 | 128 | 2.580 |
Why?
|
| Scrotum | 7 | 2021 | 13 | 2.570 |
Why?
|
| Treatment Outcome | 47 | 2022 | 2960 | 2.500 |
Why?
|
| Retrospective Studies | 40 | 2023 | 3062 | 2.480 |
Why?
|
| Adult | 78 | 2023 | 6584 | 2.380 |
Why?
|
| Urethra | 7 | 2019 | 14 | 2.370 |
Why?
|
| Injections, Intralesional | 21 | 2022 | 30 | 2.140 |
Why?
|
| Microsurgery | 10 | 2021 | 42 | 2.100 |
Why?
|
| Urethral Stricture | 6 | 2017 | 7 | 2.080 |
Why?
|
| Vasectomy | 4 | 2018 | 5 | 1.910 |
Why?
|
| Aged | 53 | 2023 | 7669 | 1.800 |
Why?
|
| Priapism | 9 | 2021 | 11 | 1.600 |
Why?
|
| Mitomycin | 3 | 2017 | 10 | 1.510 |
Why?
|
| Collagenases | 8 | 2021 | 15 | 1.500 |
Why?
|
| Algorithms | 9 | 2021 | 305 | 1.480 |
Why?
|
| Pericardium | 6 | 2019 | 15 | 1.430 |
Why?
|
| Prostatectomy | 7 | 2019 | 20 | 1.290 |
Why?
|
| Postoperative Complications | 13 | 2018 | 819 | 1.240 |
Why?
|
| Pain, Postoperative | 5 | 2018 | 294 | 1.230 |
Why?
|
| Testicular Hydrocele | 3 | 2021 | 6 | 1.230 |
Why?
|
| Pelvic Pain | 3 | 2021 | 5 | 1.190 |
Why?
|
| Genital Diseases, Male | 2 | 2021 | 7 | 1.110 |
Why?
|
| Clostridium histolyticum | 5 | 2020 | 7 | 1.070 |
Why?
|
| Prosthesis Design | 8 | 2020 | 448 | 1.060 |
Why?
|
| Ketoconazole | 3 | 2013 | 4 | 1.060 |
Why?
|
| Equipment and Supplies | 3 | 2020 | 8 | 1.050 |
Why?
|
| Nerve Block | 2 | 2021 | 61 | 1.040 |
Why?
|
| Physical Therapy Modalities | 2 | 2016 | 62 | 1.010 |
Why?
|
| Young Adult | 13 | 2021 | 1721 | 1.010 |
Why?
|
| Postoperative Period | 8 | 2019 | 317 | 1.000 |
Why?
|
| Follow-Up Studies | 19 | 2019 | 1494 | 0.990 |
Why?
|
| Urinary Bladder Diseases | 3 | 2015 | 6 | 0.980 |
Why?
|
| Intermittent Urethral Catheterization | 2 | 2015 | 2 | 0.960 |
Why?
|
| Surveys and Questionnaires | 15 | 2020 | 977 | 0.950 |
Why?
|
| Contracture | 2 | 2015 | 10 | 0.950 |
Why?
|
| Vasodilator Agents | 6 | 2011 | 19 | 0.940 |
Why?
|
| Calcium Channel Blockers | 5 | 2015 | 29 | 0.920 |
Why?
|
| Sexual Behavior | 7 | 2020 | 43 | 0.870 |
Why?
|
| Hypogonadism | 4 | 2014 | 6 | 0.870 |
Why?
|
| Practice Guidelines as Topic | 10 | 2016 | 227 | 0.840 |
Why?
|
| Prospective Studies | 15 | 2020 | 1528 | 0.840 |
Why?
|
| Testosterone | 5 | 2013 | 20 | 0.840 |
Why?
|
| Pelvis | 3 | 2017 | 25 | 0.830 |
Why?
|
| Pain, Intractable | 3 | 2012 | 8 | 0.820 |
Why?
|
| Orgasm | 2 | 2020 | 5 | 0.820 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 214 | 0.800 |
Why?
|
| Piperazines | 8 | 2012 | 64 | 0.800 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 3 | 2018 | 3 | 0.790 |
Why?
|
| Phosphodiesterase Inhibitors | 7 | 2011 | 14 | 0.790 |
Why?
|
| Research Design | 4 | 2022 | 147 | 0.780 |
Why?
|
| Patient Compliance | 3 | 2018 | 117 | 0.770 |
Why?
|
| Adolescent | 15 | 2018 | 1775 | 0.770 |
Why?
|
| Pain, Procedural | 1 | 2021 | 2 | 0.760 |
Why?
|
| Suction | 6 | 2012 | 39 | 0.740 |
Why?
|
| Pain Measurement | 7 | 2021 | 446 | 0.700 |
Why?
|
| Ultrasonography, Doppler, Duplex | 7 | 2023 | 14 | 0.690 |
Why?
|
| Urology | 4 | 2014 | 17 | 0.680 |
Why?
|
| Amphetamine | 1 | 2020 | 6 | 0.670 |
Why?
|
| Pelvic Floor | 2 | 2016 | 5 | 0.660 |
Why?
|
| Central Nervous System Stimulants | 1 | 2020 | 39 | 0.660 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2019 | 2 | 0.630 |
Why?
|
| Suburethral Slings | 1 | 2019 | 2 | 0.630 |
Why?
|
| Hemostatics | 1 | 2019 | 7 | 0.630 |
Why?
|
| Mouth Mucosa | 3 | 2008 | 11 | 0.620 |
Why?
|
| Premature Ejaculation | 1 | 2019 | 1 | 0.620 |
Why?
|
| Quality of Life | 5 | 2020 | 504 | 0.620 |
Why?
|
| Sclerotherapy | 2 | 2021 | 3 | 0.590 |
Why?
|
| Psychotherapy | 1 | 2018 | 24 | 0.590 |
Why?
|
| Testis | 4 | 2008 | 9 | 0.560 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2017 | 1 | 0.560 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 8 | 0.560 |
Why?
|
| Pain | 5 | 2013 | 370 | 0.550 |
Why?
|
| Sutures | 1 | 2017 | 47 | 0.550 |
Why?
|
| Digital Rectal Examination | 1 | 2016 | 1 | 0.540 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 13 | 0.530 |
Why?
|
| Epididymis | 4 | 2016 | 6 | 0.520 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2016 | 7 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2021 | 236 | 0.510 |
Why?
|
| Spermatozoa | 3 | 2003 | 6 | 0.500 |
Why?
|
| Recurrence | 7 | 2017 | 262 | 0.500 |
Why?
|
| Nicardipine | 1 | 2015 | 4 | 0.500 |
Why?
|
| Free Radical Scavengers | 1 | 2015 | 5 | 0.500 |
Why?
|
| Anticonvulsants | 1 | 2016 | 41 | 0.500 |
Why?
|
| Ejaculation | 4 | 2020 | 7 | 0.500 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 18 | 0.500 |
Why?
|
| Oligospermia | 3 | 2003 | 3 | 0.490 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 91 | 0.490 |
Why?
|
| Pilot Projects | 6 | 2020 | 334 | 0.480 |
Why?
|
| Glucocorticoids | 2 | 2021 | 58 | 0.480 |
Why?
|
| Iontophoresis | 4 | 2011 | 4 | 0.480 |
Why?
|
| Impotence, Vasculogenic | 3 | 2010 | 3 | 0.470 |
Why?
|
| Ischemia | 3 | 2013 | 19 | 0.470 |
Why?
|
| Vacuum | 6 | 2018 | 6 | 0.450 |
Why?
|
| Prosthesis Failure | 2 | 2012 | 478 | 0.450 |
Why?
|
| Radiotherapy | 1 | 2014 | 28 | 0.450 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 685 | 0.440 |
Why?
|
| 14-alpha Demethylase Inhibitors | 1 | 2013 | 1 | 0.430 |
Why?
|
| Postoperative Care | 5 | 2019 | 121 | 0.430 |
Why?
|
| Sulfones | 8 | 2012 | 19 | 0.420 |
Why?
|
| Calcinosis | 1 | 2013 | 34 | 0.420 |
Why?
|
| Homosexuality, Male | 1 | 2013 | 24 | 0.410 |
Why?
|
| Doxycycline | 1 | 2012 | 15 | 0.400 |
Why?
|
| Anemia, Sickle Cell | 3 | 2021 | 14 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 93 | 0.390 |
Why?
|
| Anesthetics, Local | 3 | 2021 | 78 | 0.380 |
Why?
|
| Patient Selection | 3 | 2020 | 157 | 0.380 |
Why?
|
| Administration, Oral | 4 | 2015 | 82 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 259 | 0.370 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 4055 | 0.360 |
Why?
|
| Double-Blind Method | 8 | 2013 | 295 | 0.360 |
Why?
|
| Ultrasonography | 7 | 2011 | 205 | 0.360 |
Why?
|
| Pain Management | 3 | 2017 | 125 | 0.350 |
Why?
|
| Pentoxifylline | 4 | 2011 | 6 | 0.350 |
Why?
|
| Time Factors | 6 | 2020 | 1220 | 0.350 |
Why?
|
| Drug Resistance | 1 | 2010 | 32 | 0.340 |
Why?
|
| Sexual Partners | 2 | 2020 | 17 | 0.340 |
Why?
|
| Attitude of Health Personnel | 2 | 2012 | 127 | 0.340 |
Why?
|
| Transsexualism | 1 | 2010 | 3 | 0.340 |
Why?
|
| Electric Stimulation Therapy | 3 | 2021 | 35 | 0.340 |
Why?
|
| Animals | 8 | 2021 | 3025 | 0.330 |
Why?
|
| Body Image | 2 | 2020 | 19 | 0.330 |
Why?
|
| Fibrosis | 3 | 2016 | 29 | 0.320 |
Why?
|
| Clomiphene | 1 | 2009 | 4 | 0.320 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2009 | 3 | 0.320 |
Why?
|
| Luteinizing Hormone | 1 | 2009 | 10 | 0.320 |
Why?
|
| Infertility, Male | 1 | 2009 | 5 | 0.320 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2009 | 20 | 0.320 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 31 | 0.320 |
Why?
|
| Prednisone | 1 | 2009 | 61 | 0.310 |
Why?
|
| Evidence-Based Medicine | 7 | 2022 | 149 | 0.310 |
Why?
|
| Sperm Count | 2 | 2001 | 5 | 0.310 |
Why?
|
| Primary Health Care | 2 | 2007 | 69 | 0.300 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 2020 | 7 | 0.290 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2008 | 5 | 0.290 |
Why?
|
| Social Adjustment | 1 | 2008 | 18 | 0.290 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 17 | 0.290 |
Why?
|
| Self Concept | 1 | 2008 | 33 | 0.290 |
Why?
|
| Autonomic Denervation | 1 | 2008 | 1 | 0.290 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 42 | 0.290 |
Why?
|
| United States | 7 | 2014 | 1726 | 0.290 |
Why?
|
| Referral and Consultation | 3 | 2016 | 71 | 0.290 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2007 | 1 | 0.280 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 7 | 0.280 |
Why?
|
| Cystitis | 3 | 1993 | 10 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 77 | 0.280 |
Why?
|
| Trifluoperazine | 1 | 2007 | 2 | 0.280 |
Why?
|
| Magnesium Sulfate | 1 | 2007 | 8 | 0.280 |
Why?
|
| Family Practice | 1 | 2007 | 14 | 0.280 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 39 | 0.280 |
Why?
|
| Expert Testimony | 4 | 2010 | 11 | 0.270 |
Why?
|
| Urologic Surgical Procedures | 3 | 2018 | 9 | 0.270 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 490 | 0.270 |
Why?
|
| Sperm Motility | 1 | 2006 | 3 | 0.270 |
Why?
|
| Risk Factors | 6 | 2021 | 1942 | 0.260 |
Why?
|
| Rupture | 3 | 2014 | 97 | 0.260 |
Why?
|
| Clinical Competence | 2 | 2012 | 184 | 0.260 |
Why?
|
| Disease Progression | 3 | 2019 | 554 | 0.260 |
Why?
|
| Prevalence | 3 | 2013 | 377 | 0.250 |
Why?
|
| Sildenafil Citrate | 8 | 2012 | 10 | 0.240 |
Why?
|
| Purines | 8 | 2012 | 20 | 0.240 |
Why?
|
| Organ Size | 2 | 2019 | 88 | 0.240 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 119 | 0.240 |
Why?
|
| Gels | 3 | 2015 | 9 | 0.230 |
Why?
|
| Suture Techniques | 2 | 2020 | 145 | 0.220 |
Why?
|
| Endoscopy | 2 | 2017 | 171 | 0.220 |
Why?
|
| Prosthesis-Related Infections | 2 | 2017 | 182 | 0.210 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 108 | 0.210 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2003 | 18 | 0.210 |
Why?
|
| Administration, Topical | 3 | 2015 | 16 | 0.210 |
Why?
|
| Abdominal Neoplasms | 1 | 2003 | 15 | 0.210 |
Why?
|
| Drug Combinations | 3 | 2019 | 28 | 0.210 |
Why?
|
| Antioxidants | 1 | 2003 | 56 | 0.210 |
Why?
|
| Cyclophosphamide | 3 | 1993 | 37 | 0.210 |
Why?
|
| Clinical Protocols | 2 | 2013 | 51 | 0.210 |
Why?
|
| Carboprost | 2 | 1993 | 2 | 0.200 |
Why?
|
| Tromethamine | 2 | 1993 | 3 | 0.200 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 36 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 36 | 0.200 |
Why?
|
| Female | 12 | 2020 | 12677 | 0.200 |
Why?
|
| Consensus | 4 | 2021 | 82 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 558 | 0.190 |
Why?
|
| Spermatocele | 1 | 2021 | 2 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2021 | 1621 | 0.190 |
Why?
|
| Skin Transplantation | 3 | 2014 | 10 | 0.190 |
Why?
|
| Varicocele | 2 | 2001 | 3 | 0.180 |
Why?
|
| Interferons | 2 | 2011 | 8 | 0.180 |
Why?
|
| Remission Induction | 3 | 2012 | 70 | 0.180 |
Why?
|
| Colchicine | 3 | 2011 | 8 | 0.180 |
Why?
|
| Extracorporeal Shockwave Therapy | 1 | 2021 | 4 | 0.180 |
Why?
|
| Semen | 1 | 2001 | 3 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2021 | 16 | 0.180 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 22 | 0.180 |
Why?
|
| Skin Diseases | 1 | 2021 | 24 | 0.170 |
Why?
|
| Women | 1 | 2020 | 11 | 0.170 |
Why?
|
| Tissue Transplantation | 2 | 2011 | 16 | 0.170 |
Why?
|
| Catheterization | 2 | 1997 | 37 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2018 | 260 | 0.160 |
Why?
|
| Papaverine | 3 | 2011 | 3 | 0.160 |
Why?
|
| Arginine | 2 | 2011 | 10 | 0.160 |
Why?
|
| Carnitine | 2 | 2011 | 6 | 0.160 |
Why?
|
| Prostatic Neoplasms | 4 | 2014 | 95 | 0.160 |
Why?
|
| Surgery, Plastic | 1 | 2020 | 15 | 0.160 |
Why?
|
| Counseling | 1 | 2019 | 39 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2020 | 138 | 0.160 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 1996 | 6 | 0.160 |
Why?
|
| Surgical Sponges | 1 | 2019 | 2 | 0.160 |
Why?
|
| Forecasting | 2 | 2019 | 85 | 0.160 |
Why?
|
| Injections | 3 | 2018 | 32 | 0.160 |
Why?
|
| Thrombin | 1 | 2019 | 14 | 0.160 |
Why?
|
| Fibrinogen | 1 | 2019 | 21 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 127 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 470 | 0.150 |
Why?
|
| Device Removal | 1 | 2019 | 76 | 0.150 |
Why?
|
| Urological Agents | 1 | 2018 | 2 | 0.150 |
Why?
|
| Coitus | 1 | 2018 | 3 | 0.150 |
Why?
|
| Chronic Disease | 3 | 2022 | 361 | 0.150 |
Why?
|
| PubMed | 1 | 2018 | 6 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 100 | 0.150 |
Why?
|
| Child | 4 | 2008 | 990 | 0.150 |
Why?
|
| Conservative Treatment | 1 | 2018 | 16 | 0.150 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 35 | 0.150 |
Why?
|
| Contraindications | 2 | 2011 | 25 | 0.150 |
Why?
|
| Urologists | 1 | 2018 | 3 | 0.140 |
Why?
|
| Specimen Handling | 1 | 1998 | 40 | 0.140 |
Why?
|
| Transplants | 1 | 2017 | 10 | 0.140 |
Why?
|
| Age Factors | 3 | 2011 | 657 | 0.140 |
Why?
|
| Allografts | 1 | 2019 | 203 | 0.140 |
Why?
|
| Physical Examination | 2 | 2012 | 105 | 0.140 |
Why?
|
| Surgical Flaps | 2 | 1998 | 44 | 0.140 |
Why?
|
| Reperfusion | 1 | 2016 | 6 | 0.130 |
Why?
|
| Self Care | 1 | 1997 | 75 | 0.130 |
Why?
|
| Anastomosis, Surgical | 3 | 2007 | 23 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 29 | 0.130 |
Why?
|
| Prognosis | 3 | 2012 | 630 | 0.130 |
Why?
|
| Surgeons | 1 | 2018 | 80 | 0.130 |
Why?
|
| Vasovasostomy | 1 | 2016 | 1 | 0.130 |
Why?
|
| Orchiectomy | 1 | 2016 | 4 | 0.130 |
Why?
|
| Urethral Diseases | 1 | 1996 | 3 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 1996 | 19 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 26 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 1996 | 21 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 17 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 1996 | 20 | 0.130 |
Why?
|
| Oils | 1 | 2015 | 1 | 0.130 |
Why?
|
| Pregnancy | 3 | 2003 | 303 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 23 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 82 | 0.120 |
Why?
|
| Myofibroblasts | 1 | 2015 | 3 | 0.120 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2015 | 6 | 0.120 |
Why?
|
| Nitric Oxide | 1 | 2015 | 55 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 26 | 0.120 |
Why?
|
| Collagen | 1 | 2015 | 78 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 8 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 15 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 96 | 0.110 |
Why?
|
| Hematoma | 1 | 2014 | 17 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 29 | 0.110 |
Why?
|
| Software | 1 | 1994 | 57 | 0.110 |
Why?
|
| Amputation, Traumatic | 2 | 2010 | 2 | 0.110 |
Why?
|
| Circumcision, Male | 1 | 2014 | 8 | 0.110 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1994 | 4 | 0.110 |
Why?
|
| Monitoring, Physiologic | 2 | 2009 | 63 | 0.110 |
Why?
|
| Leuprolide | 1 | 1993 | 7 | 0.110 |
Why?
|
| Ureter | 1 | 1993 | 17 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2013 | 3 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 1994 | 62 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 2014 | 121 | 0.100 |
Why?
|
| Sexuality | 1 | 2013 | 12 | 0.100 |
Why?
|
| Arteries | 3 | 2002 | 12 | 0.100 |
Why?
|
| Constriction | 2 | 2004 | 2 | 0.100 |
Why?
|
| Splints | 2 | 2004 | 2 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 1994 | 122 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 1995 | 220 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 1994 | 89 | 0.100 |
Why?
|
| Connective Tissue | 1 | 2012 | 20 | 0.100 |
Why?
|
| Mesentery | 1 | 1992 | 5 | 0.100 |
Why?
|
| Urinary Tract | 1 | 1992 | 2 | 0.100 |
Why?
|
| Reoperation | 2 | 2017 | 846 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 947 | 0.100 |
Why?
|
| Hemorrhage | 1 | 1992 | 73 | 0.100 |
Why?
|
| Medical History Taking | 2 | 2003 | 28 | 0.100 |
Why?
|
| Ligation | 2 | 2006 | 36 | 0.100 |
Why?
|
| Drug Implants | 1 | 2012 | 8 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 205 | 0.090 |
Why?
|
| Intestines | 1 | 1992 | 73 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 14 | 0.090 |
Why?
|
| Alprostadil | 1 | 1991 | 8 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 32 | 0.090 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2011 | 1 | 0.090 |
Why?
|
| Electroconvulsive Therapy | 1 | 2011 | 8 | 0.090 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 5 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2011 | 24 | 0.090 |
Why?
|
| Vitamin E | 1 | 2011 | 42 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 243 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 90 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2012 | 485 | 0.090 |
Why?
|
| Heart Failure | 1 | 2012 | 106 | 0.090 |
Why?
|
| Sexology | 1 | 2010 | 1 | 0.080 |
Why?
|
| Replantation | 1 | 2010 | 7 | 0.080 |
Why?
|
| Medicine | 1 | 2010 | 9 | 0.080 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 6 | 0.080 |
Why?
|
| Transplantation, Autologous | 2 | 2008 | 126 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 64 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 5 | 0.080 |
Why?
|
| Drug Costs | 1 | 2009 | 7 | 0.080 |
Why?
|
| Urination Disorders | 1 | 1989 | 6 | 0.080 |
Why?
|
| Smoking | 1 | 1990 | 163 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1989 | 16 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1989 | 30 | 0.080 |
Why?
|
| Retroperitoneal Space | 1 | 1988 | 4 | 0.080 |
Why?
|
| Actinomycosis | 1 | 1988 | 3 | 0.080 |
Why?
|
| Darkness | 1 | 2008 | 8 | 0.070 |
Why?
|
| Penicillins | 1 | 1988 | 9 | 0.070 |
Why?
|
| Regional Blood Flow | 3 | 1995 | 6 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 78 | 0.070 |
Why?
|
| Sclerosing Solutions | 1 | 1988 | 1 | 0.070 |
Why?
|
| Tetracycline | 1 | 1988 | 2 | 0.070 |
Why?
|
| Interview, Psychological | 1 | 2008 | 33 | 0.070 |
Why?
|
| Focus Groups | 1 | 2008 | 58 | 0.070 |
Why?
|
| Feedback | 1 | 2008 | 28 | 0.070 |
Why?
|
| Social Isolation | 1 | 2008 | 29 | 0.070 |
Why?
|
| Prostate | 1 | 2008 | 32 | 0.070 |
Why?
|
| Prejudice | 1 | 2008 | 32 | 0.070 |
Why?
|
| Abscess | 1 | 1988 | 27 | 0.070 |
Why?
|
| Cystoscopy | 1 | 2007 | 1 | 0.070 |
Why?
|
| Urography | 1 | 2007 | 3 | 0.070 |
Why?
|
| Trauma Severity Indices | 1 | 2007 | 5 | 0.070 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 21 | 0.070 |
Why?
|
| Rectum | 1 | 2007 | 45 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 92 | 0.070 |
Why?
|
| Wisconsin | 1 | 2007 | 3 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2007 | 57 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2008 | 489 | 0.070 |
Why?
|
| Illinois | 1 | 2007 | 211 | 0.070 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 3 | 0.060 |
Why?
|
| Pyrroles | 1 | 2006 | 15 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2006 | 13 | 0.060 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2001 | 588 | 0.060 |
Why?
|
| Therapeutic Irrigation | 2 | 1995 | 50 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 18 | 0.050 |
Why?
|
| Prolactin | 1 | 2003 | 3 | 0.050 |
Why?
|
| Pituitary Diseases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2003 | 3 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 19 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2003 | 12 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2003 | 13 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 6 | 0.050 |
Why?
|
| Electricity | 1 | 2003 | 6 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 45 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2003 | 32 | 0.050 |
Why?
|
| Epinephrine | 1 | 2003 | 28 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2002 | 33 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 44 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 344 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 147 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 35 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2002 | 29 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2022 | 29 | 0.050 |
Why?
|
| Hemodynamics | 2 | 2012 | 51 | 0.050 |
Why?
|
| Sex Counseling | 1 | 2000 | 1 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2000 | 28 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 40 | 0.040 |
Why?
|
| Decision Trees | 1 | 2000 | 14 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2000 | 24 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 215 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 249 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2000 | 68 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 177 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 79 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 102 | 0.040 |
Why?
|
| Radiology Department, Hospital | 1 | 1998 | 1 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 1998 | 15 | 0.040 |
Why?
|
| Urination | 1 | 1998 | 3 | 0.040 |
Why?
|
| Fascia | 1 | 1998 | 9 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 1998 | 25 | 0.040 |
Why?
|
| Incidence | 1 | 2000 | 649 | 0.040 |
Why?
|
| Reproductive Techniques | 1 | 1998 | 1 | 0.040 |
Why?
|
| Global Health | 1 | 2018 | 29 | 0.040 |
Why?
|
| Heterografts | 1 | 2017 | 11 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 1998 | 65 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 1998 | 108 | 0.040 |
Why?
|
| Urodynamics | 1 | 1997 | 2 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 1979 | 134 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 101 | 0.030 |
Why?
|
| Internet | 1 | 2018 | 79 | 0.030 |
Why?
|
| Conscious Sedation | 1 | 1997 | 3 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1997 | 7 | 0.030 |
Why?
|
| Costs and Cost Analysis | 3 | 2001 | 32 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 162 | 0.030 |
Why?
|
| Ecchymosis | 1 | 1995 | 2 | 0.030 |
Why?
|
| Ephedrine | 1 | 1995 | 5 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 16 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 401 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 1995 | 64 | 0.030 |
Why?
|
| Angiography | 1 | 1995 | 21 | 0.030 |
Why?
|
| Thrombosis | 1 | 1995 | 38 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 117 | 0.030 |
Why?
|
| Knowledge Bases | 1 | 2014 | 2 | 0.030 |
Why?
|
| Radiography | 2 | 2000 | 549 | 0.030 |
Why?
|
| Reference Values | 1 | 1994 | 152 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 368 | 0.030 |
Why?
|
| Australia | 1 | 2013 | 41 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 1993 | 5 | 0.030 |
Why?
|
| Ureteral Obstruction | 1 | 1993 | 13 | 0.030 |
Why?
|
| Hematuria | 1 | 1993 | 14 | 0.030 |
Why?
|
| Urologic Diseases | 1 | 1993 | 5 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 1993 | 61 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 1993 | 20 | 0.030 |
Why?
|
| Methods | 1 | 1992 | 9 | 0.020 |
Why?
|
| Edema | 1 | 1992 | 24 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2012 | 17 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1992 | 283 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 57 | 0.020 |
Why?
|
| Sleep | 1 | 1994 | 290 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1993 | 137 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 210 | 0.020 |
Why?
|
| Rats | 1 | 1992 | 554 | 0.020 |
Why?
|
| Veins | 1 | 1991 | 5 | 0.020 |
Why?
|
| Color | 1 | 1991 | 6 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 1990 | 9 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2007 | 1122 | 0.020 |
Why?
|
| Acrolein | 1 | 1989 | 1 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 477 | 0.020 |
Why?
|
| Clostridium | 1 | 1968 | 2 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 1968 | 6 | 0.020 |
Why?
|
| Blood | 1 | 1968 | 19 | 0.020 |
Why?
|
| Drainage | 1 | 1988 | 38 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1989 | 139 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1988 | 41 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 55 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 25 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2007 | 280 | 0.010 |
Why?
|
| Empty Sella Syndrome | 1 | 2003 | 4 | 0.010 |
Why?
|
| Pituitary Neoplasms | 1 | 2003 | 15 | 0.010 |
Why?
|
| Adenoma | 1 | 2003 | 58 | 0.010 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Pancreatic Elastase | 1 | 2002 | 2 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2002 | 4 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2002 | 23 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2002 | 20 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 107 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 78 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2001 | 29 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 82 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 118 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 166 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 143 | 0.010 |
Why?
|
| Comorbidity | 1 | 2002 | 354 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 167 | 0.010 |
Why?
|
| Palliative Care | 1 | 2001 | 94 | 0.010 |
Why?
|
| Relative Value Scales | 1 | 2000 | 4 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2000 | 38 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2000 | 12 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 227 | 0.010 |
Why?
|
| Cost Control | 1 | 1998 | 6 | 0.010 |
Why?
|
| Boston | 1 | 1998 | 18 | 0.010 |
Why?
|
| Efficiency | 1 | 1998 | 17 | 0.010 |
Why?
|
| Benchmarking | 1 | 1998 | 28 | 0.010 |
Why?
|
| Eponyms | 1 | 1998 | 1 | 0.010 |
Why?
|
| History, 16th Century | 1 | 1998 | 1 | 0.010 |
Why?
|
| History, 18th Century | 1 | 1998 | 4 | 0.010 |
Why?
|
| Wound Healing | 1 | 1979 | 140 | 0.010 |
Why?
|
| Cryptorchidism | 1 | 1993 | 3 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 1993 | 13 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1993 | 81 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1993 | 165 | 0.010 |
Why?
|
| Ducks | 1 | 1968 | 1 | 0.000 |
Why?
|
| Chromatography | 1 | 1968 | 2 | 0.000 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1968 | 4 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1968 | 8 | 0.000 |
Why?
|
| Goats | 1 | 1968 | 5 | 0.000 |
Why?
|
| Trypsin Inhibitors | 1 | 1968 | 2 | 0.000 |
Why?
|
| Horses | 1 | 1968 | 10 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1968 | 23 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1968 | 19 | 0.000 |
Why?
|
| Cricetinae | 1 | 1968 | 30 | 0.000 |
Why?
|
| Chickens | 1 | 1968 | 30 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1968 | 89 | 0.000 |
Why?
|
| Swine | 1 | 1968 | 62 | 0.000 |
Why?
|
| Cattle | 1 | 1968 | 108 | 0.000 |
Why?
|
| Rabbits | 1 | 1968 | 166 | 0.000 |
Why?
|
| Mice | 1 | 1968 | 1128 | 0.000 |
Why?
|